via Prometheus Biosciences and Pfizer are both developing experimental first-of-their-kind treatments for inflammatory bowel disease. Inflammatory bowel disease candidates from Pfizer and Prometheus Biosciences are similar, but there are a couple of key differences. Prometheus Biosciences' stock price could skyrocket this year if its candidate outperforms Pfizer's candidate. article source